Professor Munitta Muthana
Clinical Medicine, School of Medicine and Population Health
School Director of One University
Professor of Immuno-oncology
+44 114 215 9057
Full contact details
Clinical Medicine, School of Medicine and Population Health
D Floor
The Medical School
Beech Hill Road
91探花
S10 2RX
- Profile
-
For enquiries please contact - ClinMed-Operational@sheffield.ac.uk
I joined the University of 91探花 in 2002 as a post-doctoral scientist in the Immunobiology Research Unit. From 2005 I held a research position in the Tumour Targeting Group where I was awarded funding as an independent researcher from the Prostate Cancer Charity (2007) and the Medical Research Council (2010). In 2011, I was appointed as non-clinical lecturer and I am now Senior Lecturer in the Department of Oncology and Metabolism.
- Research interests
-
Our tea. 鈥楴anobug Oncology 91探花鈥 (@Nanobug_Shef) focuses on developing state-of-the-art methods to target anticancer therapies to tumours. For example, we have devised a way to use macrophages as 鈥榯rojans鈥 to deliver large quantities of cancer-killing virus to both primary and secondary tumours simultaneously (). We are currently developing innovative nanomedicine platforms to improve the targeting of drugs to tumours so that healthy tissue remains unharmed. We have used these platforms to protect and deliver oncolytic viruses via the bloodstream so that advanced metastatic cancers can be treated. These include liposomes, nanohydrogels, silk fibroin, extracellular vesicles, and magnetic nanoparticles. For the latter, we recently demonstrated that iron particles purified from magnetotactic bacteria were able to shield viruses and guide them to tumours in models of breast cancer.
Current projects
- Targeting novel oncolytic viruses to tumours.
- Using nanomagnet technology to improve tumour targeting.
- Developing novel magnetic devices for cancer.
- Using a novel microfluidic device for producing silk fibroin nanoparticles.
- Developing nanoplatforms for targeting oncolytic viruses.
- Characterisation of infiltrating subsets of monocytes/macrophages in the tumour microenvironment.
- Using immune checkpoint inhibitors in combination with oncolytic viruses.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . Small.
- . Theranostics, 12(8), 3584-3600.
- . Nanomedicine: Nanotechnology, Biology and Medicine, 40.
- . Frontiers in Endocrinology, 12.
- . Viruses, 13(6).
- . Journal for ImmunoTherapy of Cancer, 9(3).
- . International Journal of Molecular Sciences, 22(2).
- . Current Pharmaceutical Design, 25(17), 1962-1979.
- . International Journal of Pharmaceutics, 555, 322-336.
- . ACS Biomaterials Science & Engineering, 3(6), 1027-1038.
- . Proceedings of the National Academy of Sciences, 112(37), 11618-11623.
- . Nature Communications, 6(-), ---.
- . Hypoxia, 185-185.
Conference proceedings papers
All publications
Journal articles
- . Journal for ImmunoTherapy of Cancer, 12(7), e009368-e009368.
- . Expert Review of Clinical Immunology.
- . Medical Research Archives, 12(6).
- . Frontiers in Immunology, 14, 1335256.
- . ESMO Open, 8(1), 101664-101664.
- . Nanotheranostics, 7(1), 102-116.
- . Viruses, 14(12).
- . Small.
- . Theranostics, 12(8), 3584-3600.
- . Nanomedicine: Nanotechnology, Biology and Medicine, 40.
- . Frontiers in Endocrinology, 12.
- . Viruses, 13(6).
- . Bone Reports, 14, 101024.
- . Pharmaceutics, 13(3).
- . Journal for ImmunoTherapy of Cancer, 9(3).
- . Nanomaterials, 11(1).
- . International Journal of Molecular Sciences, 22(2).
- . Molecules, 26(1).
- . Journal of Bone Oncology, 25.
- . Nanomedicine, 15(1), 93-110.
- . European Urology Supplements, 18(8), e3090-e3091.
- . European Urology Supplements, 18(8), e3060-e3060.
- . Current Pharmaceutical Design, 25(17), 1962-1979.
- . The Journal of Immunology, 202(4), 1069-1078.
- . International Journal of Pharmaceutics, 555, 322-336.
- . Blood, 132(Supplement 1), 3213-3213.
- . ACS Biomaterials Science & Engineering, 3(6), 1027-1038.
- . Mediators Inflamm, 2016, 5894347-5894347.
- . Journal of Medicinal Chemistry, 58(23), 9309-9333.
- . Human Molecular Genetics, 24(19), 5367-5377.
- . Proceedings of the National Academy of Sciences, 112(37), 11618-11623.
- . Cancer Research, 75(17), 3479-3491.
- . Nature Communications, 6(-), ---.
- . Rheumatology, 53(suppl_1), i85-i85.
- . PLoS One, 9(2), e88767.
- . Angiogenesis, 17(1), 207-219.
- . Annals of the Rheumatic Diseases, 72(Suppl 3), A165.4-A166.
- . Annals of the Rheumatic Diseases, 72(Suppl 3), A199.1-A199.
- . Annals of the Rheumatic Diseases, 72(Suppl 3), A812.2-A812.
- HYPDXIA-INDUCIBLE FACTOR 2A IS PREFERENTIALLY EXPRESSED BY M2-LIKE SYNOVIAL MACROPHAGES IN RHEUMATOID ARTHRITIS. ANNALS OF THE RHEUMATIC DISEASES, 72, 199-199.
- THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS FIBROBLASTS-LIKE SYNOVIOCYTES. ANNALS OF THE RHEUMATIC DISEASES, 72, 165-166.
- . Biochem Soc Trans, 41(3), 783-788.
- . Rheumatology, 52(suppl 1), i56-i94.
- . Rheumatology, 52(suppl 1), i44-i55.
- . BIO-PROTOCOL, 3(13).
- . Cancer Res, 73(2), 490-495.
- . J Ethnopharmacol, 138(3), 780-787.
- . J Immunol, 186(7), 4183-4190.
- . Cancer Res, 71(8), 2826-2837.
- . Cancer Res, 71(5), 1805-1815.
- . Int J Hyperthermia, 26(3), 247-255.
- . Nat Rev Cancer, 8(8), 618-631.
- . Gene Ther, 15(12), 902-910.
- . Trends Biochem Sci, 33(2), 71-79.
- . Methods, 43(3), 238-244.
- . Cell Stress Chaperones, 12(1), 71-82.
- . Biochimie, 88(9), 1165-1174.
- . Cell Stress Chaperones, 11(4), 364-378.
- . Immunobiology, 211(5), 391-402.
- Gp96 prolongs rat cardiac allograft survival and modifies rejection-associated inflammatory events. IMMUNOLOGY, 116, 107-107.
- The stress protein gp96 does not activate rat bone marrow-derived dendritic cells. IMMUNOLOGY, 116, 98-98.
- . J Immunol, 175(10), 6257-6263.
- . Contrib Nephrol, 148, 122-134.
- . J Immunol Methods, 294(1-2), 165-179.
- . Immunology, 109(1), 41-48.
- Pilot study: Immunisation with melanoma associated peptides and GM-CSF in HLA-A2 patients with metastatic melanoma.. BRIT J CANCER, 86, S115-S115.
- Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells.. Cancer Res, 60(22), 6441-6447.
- . Viruses, 16(8), 1264-1264.
- . Pharmaceutics, 15(7), 1811-1811.
- . Frontiers in Virology, 3, 1180815.
- . Viruses, 15(3), 603-603.
- . Future Pharmacology, 2(4), 444-459.
- . Viruses, 14(7), 1493-1493.
- . Frontiers in Molecular Biosciences, 9.
- .
- . Hypoxia, 185-185.
- . Molecular Cancer Therapeutics, molcanther.0748.2020-molcanther.0748.2020.
Chapters
- , Systemic Drug Delivery Strategies (pp. 211-230). Elsevier
- , Tumor Immunology and Immunotherapy (pp. 43-62). Oxford University Press
- , Tumour-Associated Macrophages (pp. 17-29). Springer New York
- , Heat Shock Proteins: Potent Mediators of Inflammation and Immunity (pp. 309-320). Springer Netherlands
- , Cell Stress Proteins (pp. 377-395). Springer New York
- , Biomedical Engineering IntechOpen
- , Liposomes - Recent Advances, New Perspectives and Applications [Working Title] IntechOpen
Conference proceedings papers
- . Annals of Oncology, Vol. 34 (pp S1177-S1177)
- . Tumor Biology
- Changes in the phenotype of macrophages and CD8+T Cells in the perivascular niche of prostate tumours following androgen deprivation.. CANCER RESEARCH, Vol. 81(13)
- . Lung Cancer
- . Immunology
- . Tumor Biology
- . Tumor Biology
- . Tumor Biology
- . Tumor Biology
- . Immunology
- Myeloma-specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 97-97)
- . European Journal of Cancer, Vol. 92 (pp S4-S4)
- Hypoxia-induced changes in astrocytes and their role in the formation of age-associated white matter lesions. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, Vol. 44 (pp 17-18)
- The Rheumatoid Arthritis Susceptibility Gene C5orf30 Is an Immunomodulator in Macrophages. ARTHRITIS & RHEUMATOLOGY, Vol. 69
- . Tumor Biology
- . Annals of the Rheumatic Diseases, Vol. 75(Suppl 2) (pp 107.1-107)
- . Journal of Clinical Oncology, Vol. 33(15_suppl) (pp e14035-e14035)
- . Annals of the Rheumatic Diseases, Vol. 73(Suppl 2) (pp 174.2-174)
- . Annals of the Rheumatic Diseases, Vol. 73(Suppl 2) (pp 361.3-361)
- . Annals of the Rheumatic Diseases, Vol. 73(Suppl 2) (pp 517.2-517)
- . Rheumatology, Vol. 53(suppl_1) (pp i147-i147)
- INVESTIGATION OF THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. RHEUMATOLOGY, Vol. 53 (pp 85-85)
- BIOLOGICAL ROLES OF C5ORF30 IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. RHEUMATOLOGY, Vol. 53 (pp 147-147)
- Acidification enhances acid sensing protein and matrix metalloproteinase expression in human rheumatoid fibroblast like synoviocytes. Annals of the Rheumatic Diseases, Vol. 73(Supplement 2) (pp 511-511)
- . Annals of the Rheumatic Diseases, Vol. 72(Suppl 3) (pp A190.2-A190)
- The biological role of C5orf30 in rheumatoid arthritis pathogenesis. IMMUNOLOGY, Vol. 140 (pp 45-45)
- Biological Roles of C5orf30 In Rheumatoid Arthritis Synovial Fibroblasts. ARTHRITIS AND RHEUMATISM, Vol. 65 (pp S1232-S1233)
- Investigation Of The Role Of Histone Deacetylases In Rheumatoid Arthritis Synovial Fibroblasts. ARTHRITIS AND RHEUMATISM, Vol. 65 (pp S1035-S1036)
- Investigation of the role of histone deacetylases in rheumatoid arthritis synovial fibroblasts. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 94(5) (pp A3-A3)
- TISSUE LOCALISATION OF ACID SENSING PROTEINS IN SYNOVIAL BIOPSIES FROM PATIENTS WITH RHEUMATOID ARTHRITIS. ANNALS OF THE RHEUMATIC DISEASES, Vol. 72 (pp 812-812)
- THE ROLE OF C5ORF30 IN RHEUMATOID ARTHRITIS PATHOGENESIS. ANNALS OF THE RHEUMATIC DISEASES, Vol. 72 (pp 190-190)
- BIOLOGICAL ROLES OF C5ORF30 IN RHEUMATOID ARTHRITIS. RHEUMATOLOGY, Vol. 52 (pp 50-50)
- INVESTIGATION OF THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. RHEUMATOLOGY, Vol. 52 (pp 79-80)
- MACROPHAGES IN HYPOXIC RHEUMATOID JOINTS PREFERENTIALLY EXPRESS HYPOXIA-INDUCIBLE TRANSCRIPTION FACTOR-2. RHEUMATOLOGY, Vol. 52 (pp 78-78)
- Biological Roles of C5orf30 in Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, Vol. 64(10) (pp S767-S767)
- Macrophages in Hypoxic Rheumatoid Joints Preferentially Express Hypoxia Inducible Transcription Factor-2. ARTHRITIS AND RHEUMATISM, Vol. 64(10) (pp S767-S767)
- . BONE, Vol. 50 (pp S191-S191)
- C5orf30 a Candidate Susceptibility Gene in Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, Vol. 63(10) (pp S719-S719)
- . DRUG DISCOVERY TODAY, Vol. 15(23-24) (pp 1097-1098)
- Engineering Macrophages to Synthesize Recombinant Adenoviruses in Hypoxic Areas of Human Prostate Tumours. HUMAN GENE THERAPY, Vol. 21(4) (pp 488-488)
- Magnetite nanoparticle-loaded macrophages enhance gene delivery to tumours. IMMUNOLOGY, Vol. 120 (pp 82-82)
- Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumors. CANCER RESEARCH, Vol. 66(8)
Other
Preprints
- Teaching interests
-
I teach Immunology on the MBChB course and I am module lead for Phase 2a immunology. I also deliver the cell-based therapies, Gene Therapy, Animal models in Research and Tumour Immunology lectures for the medical school MSc. Molecular Medicine, MSc. Translational Oncology, MSc. Advanced Cell and Gene therapy, MSc Translational Neuroscience.
- Professional activities and memberships
-
- American Association of Cancer Research (AACR).
- British Society of Immunology (BSI).
- European Macrophage and Dendritic Cell Society and British Society of Immunology.